climbed 28.5% to $6.40 after the company announced positive finding from an expanded study of its non-alcoholic steatohepatitis, or NASH, drug candidate CRV 431 with human precision cut liver slices.

More 62 Stocks Moving In Tuesday’s Mid-Day Session Videos